# Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.

> **NCT07267221** · PHASE1 · RECRUITING · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 36 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** DWJ1622
- **DRUG:** DWC202313, DWC202314

## Key facts

- **NCT ID:** NCT07267221
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2026-01-30
- **Final completion:** 2026-05-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07267221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07267221, "Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07267221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*